120 related articles for article (PubMed ID: 35755075)
1. Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.
Shehab M; Alrashed F; Abdullah I; Alfadhli A; Ali H; Abu-Farha M; Channanath AM; Abubaker JA; Al-Mulla F
Front Med (Lausanne); 2022; 9():881027. PubMed ID: 35755075
[TBL] [Abstract][Full Text] [Related]
2. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events Following BNT162b2 mRNA COVID-19 Vaccine Immunization among Healthcare Workers in a Tertiary Hospital in Johor, Malaysia.
Tan AY; Chang CT; Yu YK; Low YX; Razali NFM; Tey SY; Lee SWH
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455258
[TBL] [Abstract][Full Text] [Related]
6. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
7. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
8. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
Hui AM; Li J; Zhu L; Tang R; Ye H; Lin M; Ge L; Wang X; Peng F; Wu Z; Guo X; Shi Y; Pan H; Zhu J; Song Z; Qiu J; Wang W; Zheng J; Ozhelvaci O; Shpyro S; Bushway M; Derhovanessian E; Kühnle MC; Luxemburger U; Muik A; Shishkova Y; Khondker Z; Hu S; Lagkadinou E; Şahin U; Türeci Ö; Zhu F
Lancet Reg Health West Pac; 2022 Dec; 29():100586. PubMed ID: 36120090
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
Ludwikowska KM; Popiel A; Matkowska-Kocjan A; Olbromski MJ; Biela M; Wójcik M; Szenborn F; Wielgos K; Pielka-Markiewicz E; Zaryczański J; Kursa MB; Szenborn L
Vaccine; 2023 Mar; 41(13):2289-2299. PubMed ID: 36870876
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study.
Shehab M; Abu-Farha M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Alphonse Thanaraj T; Channanath A; Ali H; Abubaker J; Almulla F
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830644
[TBL] [Abstract][Full Text] [Related]
13. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes.
Emeksiz HC; Hepokur MN; Şahin SE; Şirvan BN; Çiçek B; Önder A; Yıldız M; Aksakal DK; Bideci A; Ovalı HF; İşman F
Front Pediatr; 2023; 11():1191706. PubMed ID: 37435175
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
17. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
[TBL] [Abstract][Full Text] [Related]
18. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
19. Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy.
Toussia-Cohen S; Yinon Y; Peretz-Machluf R; Segal O; Regev N; Asraf K; Doolman R; Kubani Y; Gonen T; Regev-Yochay G; Bookstein Peretz S
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36012958
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study.
Pellegrino R; Pellino G; Selvaggi L; Selvaggi F; Federico A; Romano M; Gravina AG
Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1243-1252. PubMed ID: 36047032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
